Elanco Animal Health has taken a major step in the booming canine dermatology market with USFDA approval of Befrena (tirnovetmab), a monoclonal antibody injection designed to treat allergic and atopic dermatitis in dogs.

The treatment stands out with a recommended dosing interval of 6 to 8 weeks, compared with the 4 to 8 weeks of its main competitor, lokivetmab.

“The animal health sector is increasingly focused on antibody-based therapies, and today's approval is an important step forward in delivering high-impact innovation that enhances the quality of life for pets,” said Dr Ellen de Brabander, Elanco’s Executive VP of Research & Development.

“We are pleased to offer veterinarians and pet owners Befrena, which delivers long lasting relief to treat dogs with allergic itch.”

Befrena marks Elanco’s second dermatology product approval in less than 18 months, joining Zenrelia (ilunocitinib tablets), a once-daily oral JAK inhibitor for controlling itching and inflammation in dogs over 12 months old.

In September, the FDA updated Zenrelia’s label, removing the risk of fatal vaccine-induced disease from modified live virus vaccines. The Boxed Warning continues to advise stopping Zenrelia 28 days to 3 months before vaccination and waiting at least 28 days after vaccination to resume.

Elanco expects Befrena to launch in the US in the first half of 2026, reinforcing its leadership in canine dermatology and monoclonal antibody therapies.

Earlier this year, Elanco released the America’s Itchy Dogs Report, a first-of-its-kind study revealing that 9 in 10 dogs in the U.S. experience itchiness during the year. Owners often spend an average of $400 on over-the-counter remedies and wait six weeks before seeking veterinary care.

Veterinarians note that this delay frequently leads to raw and infected skin, as well as frustrated owners eager for faster relief. Nearly 70% of veterinarians surveyed said they would stock another dermatology product to help more dogs find relief.

“Veterinarians need more options for itch relief so they can offer targeted therapy that focuses on mode of action to meet the unique needs of the individual patient to deliver fast, effective and valuable itch relief,” said Dr Griffin, veterinary dermatologist.

“USDA approval of Befrena brings veterinarians a step closer to having another beneficial and safe treatment option. I'm excited to collaborate with Elanco and plan to offer this product in my practice when it becomes available.”